Abstract
This retrospective study investigates the frequency and prognostic significance of deficient mismatch repair (dMMR) and RAS mutations in a cohort of 813 colorectal carcinoma (CRC) patients from Eastern China. Using immunohistochemistry and real-time PCR, we identified a dMMR rate of 15.18% and a RAS mutation rate of 45.88%. While these biomarkers correlate strongly with specific clinicopathological features—such as age, tumor location, and mucinous production—they did not serve as independent prognostic factors for survival in stage I–III patients. These findings provide critical population-specific data for the management of CRC in China.
Introduction
Colorectal cancer (CRC) is a leading cause of cancer-related mortality in China, characterized by a highly heterogeneous molecular landscape. Understanding this landscape is crucial for personalized medicine. Two major pathways drive CRC pathogenesis: the mismatch repair (MMR) pathway and the RAS signaling pathway.
Deficiencies in the MMR system (dMMR) lead to the accumulation of DNA replication errors, a condition known as microsatellite instability (MSI). Conversely, mutations in the RAS gene family (specifically KRAS and NRAS) result in the constitutive activation of downstream signaling, which often renders tumors resistant to anti-EGFR targeted therapies. While these biomarkers are well-characterized in Western populations, data from Chinese cohorts have been inconsistent, with some studies reporting lower frequencies of dMMR. This study addresses the need for large-scale, population-specific data to help clinicians in China better predict disease progression and tailor treatments.
Methodology
The researchers conducted a retrospective analysis of 813 CRC patients treated at the Affiliated Hospital of Qingdao University between 2013 and 2016. The study utilized formalin-fixed, paraffin-embedded tumor specimens and employed two primary diagnostic techniques:
- Immunohistochemistry (IHC): To detect the expression of four key MMR proteins: MLH1, PMS2, MSH2, and MSH6. A tumor was categorized as dMMR if it showed a complete loss of nuclear staining in any of these proteins.
- ARMS-PCR (Amplification Refractory Mutation System): A highly sensitive real-time PCR method used to identify specific mutations in KRAS (codons 12, 13) and NRAS (codons 12, 13, 61).
Statistical analyses were performed using Chi-square tests for categorical variables and Kaplan–Meier survival curves with log-rank tests to evaluate Disease-Free Survival (DFS) and Overall Survival (OS) for 729 patients with stage I–III disease.
Key Results
Biomarker Frequency and Distribution
- dMMR Prevalence: The overall frequency of dMMR was 15.18% (121/797). This rate is comparable to Western data (15-20%) and higher than previously reported in some smaller Chinese studies.
- RAS Mutational Profile: The overall RAS mutation rate was 45.88%. This was predominantly driven by KRAS mutations (42.56%), while NRAS mutations were relatively rare (3.69%).
Clinicopathological Correlations
- The "Young and Right" Phenotype: dMMR was significantly more common in patients under 50 years of age (p < 0.001) and in tumors located on the right side of the colon (p < 0.001). This aligns with the "Lynch Syndrome" profile observed globally.
- Tumor Morphology: dMMR status was strongly associated with mucinous production (p < 0.001), poor cell differentiation (p < 0.001), and early tumor stage (p < 0.05).
- KRAS Specifics: KRAS mutations were significantly associated with mucinous production and tumor stage. Interestingly, mutation rates were higher in non-smokers (p < 0.05) and patients with a family history of CRC (p < 0.05).
Survival Outcomes
A key finding of the study was the lack of prognostic significance for these markers in stage I–III patients. There was no statistically significant difference in DFS or OS based on dMMR status (p=0.16) or KRAS mutation status (p=0.47).
Discussion
The findings confirm that the molecular profile of CRC in Eastern China largely mirrors global trends, particularly regarding the clinical phenotype of dMMR tumors. However, the "prognostic gap"—the lack of survival correlation for dMMR in early-stage patients—contrasts with many Western studies where dMMR typically signals a better prognosis. This discrepancy suggests that regional genetic variations, environmental factors, or differences in standard-of-care treatments may influence the prognostic value of these markers.
Additionally, the near-mutual exclusivity of dMMR and NRAS mutations suggests distinct evolutionary trajectories for these tumor subtypes. The association of KRAS mutations with non-smokers and family history further emphasizes the complex interplay between genetics and lifestyle in CRC development within the Chinese population.
Conclusion
This study provides a robust baseline for the molecular characterization of CRC in Eastern China. While dMMR and RAS mutations are essential tools for predicting clinical phenotypes and guiding targeted therapy, their role as independent prognostic factors in stage I–III disease requires further validation. Future multi-center studies with expanded mutational testing (extended RAS) and controlled treatment variables are necessary to further refine these prognostic models for the Chinese population.
Summary updated